Biobetters in Key Markets - Opportunities for Biotechnology Companies to Sustain Innovation with Low Risk and High Value Offerings


July 10, 2012
82 Pages - SKU: XGBR3958735
License type:
Table of Contents Search inside this report Related Reports Detailed Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
3 Global Market Overview
3.1 Biobetter Therapies Already on the Market
3.1.1 Erythropoietins
3.1.2 Granulocyte-colony Stimulating Factors
3.1.3 Interferon-a, Interferon-ß
3.1.4 Insulin and Insulin Analogs
3.1.5 Monoclonal Antibodies
3.1.6 TNF-a Inhibitors
3.2 Promising Drug Classes for Biobetter Therapies
3.2.1 Human Growth Hormone
3.3 Comparison of Biosimilars and Biobetters
4 Technology Analysis
4.1 Introduction
4.1.1 Host Cell
4.1.2 Glycosylation
4.1.3 PEGylation
4.1.4 Polysialylation
4.1.5 Fusion Protein
4.1.6 PASylation
4.1.7 HESylation
5 Challenges and Opportunities
5.1 Opportunities
5.1.1 Biobetter Therapies Gain Substantial Market Shares upon Launch
5.1.2 Higher Success Rates in the Development of Biobetter Therapies
5.2 Challenges
5.2.1 Uncertainty Surrounding the Implementation of the Affordable Care Act will Limit Patient Access to Biobetter Drugs
5.2.2 Growing Debts and the Slowing of the Economy will Drive Governmental Bodies and Healthcare Providers to Restrict the Use of Expensive Biobetter Therapies
5.2.3 Regulatory Policies in Emerging Economies such as China and India do not Provide Enough Protection for the Development of Biobetter Therapies
6 Pipeline Analysis
6.1 Introduction3
6.2 Human Growth Hormone
6.3 Erythropoietin
6.4 Granulocyte-colony Stimulating Factor
6.5 Interferon-a and Interferon-ß
6.6 Insulin and Insulin Analogs
6.7 Monoclonal Antibodies
6.8 Promising Drugs
6.8.1 LB03002 - HGH
6.8.2 Degludec - Insulin Analog
6.8.3 Theracim - Monoclonal Antibody
6.8.4 Pertuzumab - Monoclonal Antibody
6.8.5 RG7159 - Monoclonal Antibody
7 The US Regulatory Environment and Approval Pathways
7.1 Introduction
7.2 Biobetter Therapies
7.3 Biosimilar Therapies
8 The EU Regulatory Environment and Approval Pathways
8.1 Introduction
8.2 Biobetter Therapies
8.3 Biosimilar Therapies
9 Japan Regulatory Environment and Approval Pathways
9.1 Biobetter Therapies
9.2 Biosimilar Therapies
10 Australia Regulatory Environment and Approval Pathways
10.1 Biobetter Therapies
10.2 Biosimilar Therapies
11 China Regulatory Environment and Approval Pathways
11.1 Biobetter Therapies
11.2 Biosimilar Therapies
12 India Regulatory Environment and Approval Pathways
12.1 Biobetter Therapies
12.2 Biosimilar Therapies
13 Biobetter Companies
13.1 Key Players
13.1.1 Amgen
13.1.2 SWOT Analysis
13.1.3 Merck
13.1.4 SWOT Analysis
13.1.5 Roche
13.1.6 SWOT Analysis
13.1.7 Novo Nordisk
13.1.8 SWOT Analysis
13.1.9 Sanofi-Aventis
13.1.10 SWOT Analysis
14 Strategic Consolidations
14.1 Deals Analysis
14.1.1 Mergers and Acquisitions
14.1.2 Licensing Agreements
15 Biobetters Therapeutics Market to 2018 - Appendix
15.1 Abbreviations
15.2 Sources
15.3 Research Methodology
15.3.1 Coverage
15.3.2 Secondary Research
15.3.3 Primary Research
15.3.4 Forecasts
15.3.5 Expert Panel Validation
15.4 Contact Us
15.5 Disclaimer
1.1 List of Tables
Table 1: Biobetters in Key Markets, Human Growth Hormone Therapeutics Pipeline, Development-stage Molecules, 2012
Table 2: Biobetters in Key Markets, Erythropoietin Pipeline, Development-stage Molecules, 2012
Table 3: Biobetters in Key Markets, Granulocyte-colony Stimulating Factor Pipeline, Development-stage Molecules, 2012
Table 4: Biobetters in Key Markets, Interferon-a and ß Pipeline, Development-stage Molecules, 2012
Table 5: Biobetters in Key Markets, Insulin Pipeline, Development-stage Molecules, 2012
Table 6: Biobetters in Key Markets, Monoclonal Antibodies Pipeline, Development-stage Molecules, 2012
Table 7: Biobetters in Key Markets, Monoclonal Antibodies Pipeline, Development-stage Molecules, 2012 (Contd.)
1.2 List of Figures
Figure 1: Biobetters in Key Markets, Erythropoietin, Global, Revenue Sales ($m), 2000-2011
Figure 2: Biobetters in Key Markets, Granulocyte-colony Stimulating Factor, Global, Revenue Sales ($m), 2000-2011
Figure 3: Biobetters in Key Markets, Interferon-alpha, Global, Revenue Sales ($m), 2000-2011
Figure 4: Biobetters in Key Markets, Insulin and Insulin Analogs, Global, Revenue Sales ($m), 2000-2011
Figure 5: Biobetters in Key Markets, Monoclonal Antibodies, Global, Revenue Sales ($m), 2004-2011
Figure 6: Biobetters in Key Markets, Monoclonal Antibodies (TNF-a) Global, Revenue Sales ($m), 2000-2011
Figure 7: Biobetters in Key Markets, Human Growth Hormone, Global, Revenue Sales ($m), 2000-2011
Figure 8: Biobetters in Key Markets, Human Growth Hormone Market, EU-5, Annual Cost of Treatment ($), 2011
Figure 9: Biobetters in Key Markets, Interferon-a Market, US, Annual Cost of Treatment ($), 2011
Figure 10: Biobetters in Key Markets, Human Growth Hormone Therapeutics, Global R&D Pipeline by Phase (%), 2011
Figure 11: Biobetters in Key Markets, Erythropoietin Therapeutics, Global R&D Pipeline by Phase (%), 2011
Figure 12: Biobetters in Key Markets, Granulocyte-colony Stimulating Factor Therapeutics, Global R&D Pipeline by Phase (%), 2011
Figure 13: Biobetters in Key Markets, Interferon-a Therapeutics, Global R&D Pipeline by Phase (%), 2011
Figure 14: Biobetters in Key Markets, Insulin and Insulin Analog Therapeutics, Global R&D Pipeline by Phase (%), 2011
Figure 15: Biobetters In Key Markets, Monoclonal Antibodies Therapeutics, Global R&D Pipeline by Phase (%), 2011
Figure 16: Biobetters in Key Markets, SWOT Analysis, Amgen, 2011
Figure 17: Biobetters in Key Markets, SWOT Analysis, Merck, 2011
Figure 18: Biobetters in Key Markets, SWOT Analysis, Roche, 2011
Figure 19: Biobetters in Key Markets, SWOT Analysis, Novo Nordisk, 2011
Figure 20: Biobetters in Key Markets, SWOT Analysis, Sanofi, 2011
Figure 21: GBI Research Market Forecasting Model
 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Biopharmacology Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!